Cargando…

Relationship of Platelet Reactivity With Bleeding Outcomes During Long‐Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non‐ST‐Segment Elevation Acute Coronary Syndromes

BACKGROUND: The relationship between “on‐treatment” low platelet reactivity and longitudinal risks of major bleeding dual antiplatelet therapy following acute coronary syndromes remains uncertain, especially for patients who do not undergo percutaneous coronary intervention. METHODS AND RESULTS: We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cornel, Jan H., Ohman, E. Magnus, Neely, Benjamin, Jakubowski, Joseph A., Bhatt, Deepak L., White, Harvey D., Ardissino, Diego, Fox, Keith A.A., Prabhakaran, Dorairaj, Armstrong, Paul W., Erlinge, David, Tantry, Udaya S., Gurbel, Paul A., Roe, Matthew T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210327/ https://www.ncbi.nlm.nih.gov/pubmed/27815268 http://dx.doi.org/10.1161/JAHA.116.003977

Ejemplares similares

Personalized antiplatelet therapy: state of the art
por: Gurbel, Paul A, et al.
Publicado: (2012)

State of the art: Oral antiplatelet therapy
por: Gurbel, Paul A, et al.
Publicado: (2016)

Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus
por: Jung, Jung Hwa, et al.
Publicado: (2015)

Temporal Variability of Platelet Reactivity Phenotype: Another Barrier to Personalized Antiplatelet Strategy Guided by Platelet Function Testing
por: Jeong, Young-Hoon, et al.
Publicado: (2019)

In Vitro Evidence for the Role of Cytokine Storm in the Generation of Stent Thrombosis in COVID-19 Patients
por: Gurbel, Paul A., et al.
Publicado: (2022)

Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome
por: Roy, Ambuj, et al.
Publicado: (2015)

Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases
por: Gurbel, Paul A, et al.
Publicado: (2010)

Further evidence for the use of aspirin in COVID-19
por: Tantry, Udaya S., et al.
Publicado: (2022)

International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests
por: Gurbel, Paul A., et al.
Publicado: (2021)

Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study
por: Gurbel, Paul A., et al.
Publicado: (2018)

Another Unmet Need against Residual Risk of Atherosclerotic Cardiovascular Disease: Can “Thrombin Pathway” Be a New Target for Therapy?
por: Kim, Hyun Kuk, et al.
Publicado: (2020)

IS THERE A ROLE FOR α1-ANTITRYPSIN IN COVID-19?
por: Gurbel, Paul A., et al.
Publicado: (2021)

AGE-BASED RISK FACTORS FOR SYMPTOMATIC COVID-19 IN THE MINORITY POPULATION
por: Gurbel, Paul A., et al.
Publicado: (2021)

Prevalence of adverse events during ticagrelor versus clopidogrel treatment and its association with premature discontinuation of dual antiplatelet therapy in East Asian patients with acute coronary syndrome
por: Kang, Min Gyu, et al.
Publicado: (2022)

Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements
por: Becker, Kristian C., et al.
Publicado: (2020)

IS LOW DOSE ASPIRIN EFFECTIVE IN REDUCING IN-HOSPITAL CLINICAL OUTCOMES IN PATIENTS WITH COVID-19?
por: Gurbel, Paul A., et al.
Publicado: (2021)

Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent
por: Tantry, Udaya S, et al.
Publicado: (2021)

Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations
por: Chaudhary, Rahul, et al.
Publicado: (2020)

Influence of Race and Sex on Thrombogenicity in a Large Cohort of Coronary Artery Disease Patients
por: Lev, Eli I., et al.
Publicado: (2014)

Effects of Monotherapy with Clopidogrel vs. Aspirin on Vascular Function and Hemostatic Measurements in Patients with Coronary Artery Disease: The Prospective, Crossover I-LOVE-MONO Trial
por: Park, Hyun-Woong, et al.
Publicado: (2021)

Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences
por: Kim, Hyun Kuk, et al.
Publicado: (2021)

Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population
por: Gurbel, Paul A., et al.
Publicado: (2021)

Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes
por: Usman, Abira, et al.
Publicado: (2022)

High-Dose, but Not Low-Dose, Aspirin Impairs Anticontractile Effect of Ticagrelor following ADP Stimulation in Rat Tail Artery Smooth Muscle Cells
por: Grześk, Grzegorz, et al.
Publicado: (2013)

First Experience Addressing the Prognostic Utility of Novel Urinary Biomarkers in Patients With COVID-19
por: Tantry, Udaya S, et al.
Publicado: (2021)

Novel Antiplatelet Therapies for Atherothrombotic Diseases
por: Majithia, Arjun, et al.
Publicado: (2019)

Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
por: Artang, Ramin, et al.
Publicado: (2021)

Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens
por: Heramvand, Nadia, et al.
Publicado: (2022)

Post-ERCP Bleeding in the Era of Multiple Antiplatelet Agents
por: Oh, Hyoung-Chul, et al.
Publicado: (2018)

Dual Antiplatelet Therapy (DAPT) versus No Antiplatelet Therapy and Incidence of Major Bleeding in Patients on Venoarterial Extracorporeal Membrane Oxygenation
por: Staudacher, Dawid L., et al.
Publicado: (2016)

Anticoagulants/antiplatelets: Bleeding: 14 case reports
Publicado: (2020)

Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors
por: Pasea, Laura, et al.
Publicado: (2017)

Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia
por: Woodhouse, Lisa J., et al.
Publicado: (2023)

Genetic testing in antiplatelet therapy – not effective for perioperative bleeding
por: Kuliczkowski, Wiktor
Publicado: (2017)

Antiplatelets/enoxaparin-sodium: Major bleeding: case report
Publicado: (2020)

The stent in the high-bleeding risk patient: antiplatelet monotherapy?
por: Capranzano, Piera
Publicado: (2022)

Novel aspects of antiplatelet therapy in cardiovascular disease
por: Gremmel, Thomas, et al.
Publicado: (2018)

Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials
por: Navarese, Eliano Pio, et al.
Publicado: (2012)

Case‐fatality rate of major bleeding events in patients on dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and meta‐analysis
por: Tritschler, Tobias, et al.
Publicado: (2022)

Dual Antiplatelet Therapy and the Severity Risk of Lower Intestinal Bleeding
por: Carlin, Neal, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h7mpt2meetfrcv3e4eijobe3sl